Anti-NPL monoclonal antibody
Pre-made anti-NPL monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to NPL/NPL products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-IP2630-Ab-1/ GM-Tg-hg-IP2630-Ab-2 | Anti-Human NPL monoclonal antibody | Human |
GM-Tg-rg-IP2630-Ab-1/ GM-Tg-rg-IP2630-Ab-2 | Anti-Rat NPL monoclonal antibody | Rat |
GM-Tg-mg-IP2630-Ab-1/ GM-Tg-mg-IP2630-Ab-2 | Anti-Mouse NPL monoclonal antibody | Mouse |
GM-Tg-cynog-IP2630-Ab-1/ GM-Tg-cynog-IP2630-Ab-2 | Anti-Cynomolgus/ Rhesus macaque NPL monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-IP2630-Ab-1/ GM-Tg-felg-IP2630-Ab-2 | Anti-Feline NPL monoclonal antibody | Feline |
GM-Tg-cang-IP2630-Ab-1/ GM-Tg-cang-IP2630-Ab-2 | Anti-Canine NPL monoclonal antibody | Canine |
GM-Tg-bovg-IP2630-Ab-1/ GM-Tg-bovg-IP2630-Ab-2 | Anti-Bovine NPL monoclonal antibody | Bovine |
GM-Tg-equg-IP2630-Ab-1/ GM-Tg-equg-IP2630-Ab-2 | Anti-Equine NPL monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-IP2630-Ab-1/ GM-Tg-hg-IP2630-Ab-2; GM-Tg-rg-IP2630-Ab-1/ GM-Tg-rg-IP2630-Ab-2; GM-Tg-mg-IP2630-Ab-1/ GM-Tg-mg-IP2630-Ab-2; GM-Tg-cynog-IP2630-Ab-1/ GM-Tg-cynog-IP2630-Ab-2; GM-Tg-felg-IP2630-Ab-1/ GM-Tg-felg-IP2630-Ab-2; GM-Tg-cang-IP2630-Ab-1/ GM-Tg-cang-IP2630-Ab-2; GM-Tg-bovg-IP2630-Ab-1/ GM-Tg-bovg-IP2630-Ab-2; GM-Tg-equg-IP2630-Ab-1/ GM-Tg-equg-IP2630-Ab-2 |
Products Name | Anti-NPL monoclonal antibody |
Format | mab |
Target Name | NPL |
Protein Sub-location | Introcelluar Protein |
Category of antibody | |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
Tag | Fc |
Products description | Pre-made anti-NPL monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-IP2630-Ag-1 | Recombinant multi-species NPL/ C112/ C1orf13 protein |
ORF Viral Vector | vGMLP000830 | human NPL Lentivirus particle |
ORF Viral Vector | pGMLP000830 | human NPL Lentivirus plasmid |
ORF Viral Vector | pGMLPm000421 | mouse Npl Lentivirus plasmid |
ORF Viral Vector | vGMLPm000421 | mouse Npl Lentivirus particle |
Target information
Target ID | GM-IP2630 |
Target Name | NPL |
Gene ID | 80896,74091,304860,106994586,490313,101091498,507597,100051658 |
Gene Symbol and Synonyms | 0610033B02Rik,C112,C1orf13,NAL,NPL,NPL1 |
Uniprot Accession | Q9BXD5,Q66H59,Q29RY9 |
Uniprot Entry Name | NPL_HUMAN,NPL_RAT,NPL_BOVIN |
Protein Sub-location | Introcelluar Protein |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000135838 |
Target Classification | N/A |
The target: NPL, gene name: NPL, also named as C112, C1orf13, NAL1, NPL. This gene encodes a member of the N-acetylneuraminate lyase sub-family of (beta/alpha)(8)-barrel enzymes. N-acetylneuraminate lyases regulate cellular concentrations of N-acetyl-neuraminic acid (sialic acid) by mediating the reversible conversion of sialic acid into N-acetylmannosamine and pyruvate. A pseudogene of this gene is located on the short arm of chromosome 2. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene. [provided by RefSeq, Jan 2011].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.